Good evening :)
Switch to
Place Order

Cadila Healthcare Ltd

CADILAHC
Health CarePharmaceuticals
LargecapWith a market cap of ₹52,128 cr, stock is ranked 95
Low RiskStock is 1.97x as volatile as Nifty
491.7017.50 (-3.44%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
LargecapWith a market cap of ₹52,128 cr, stock is ranked 95
Low RiskStock is 1.97x as volatile as Nifty

Key Metrics

PE RatioPE Ratio
24.43
PB RatioPB Ratio
3.49
Dividend YieldDiv. Yield
0.69%
Sector PESector PE
38.44
Sector PBSector PB
5.13
Sector Div YldSctr Div Yld
0.68%

Forecast & RatingsDetailed Forecast 

45%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Cadila Healthcare Limited is a pharmaceutical company.

Brands

Cadila

Pharmaceutical company

Zydus Cadila

Investor PresentationView older 

Aug 11, 2021

PDF
View Older Presentations

Brands

Cadila

Pharmaceutical company

Zydus Cadila

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Financial TrendFinancial statements 

201820192020202112.0213.3714.3715.141.781.851.182.13
Revenue
Profit
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Decreased Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has decreased by 1.04%

See detailed holdings

Recent EventsAll events 

Analysts/Institutional Investor Meet/Con. Call Updates 
Announced OnOct 23, 2021

Cadila Healthcare Limited has informed the Exchange about Schedule of meet | Download

Cadila Healthcare Limited has informed the Exchange about Schedule of meet | Download

Press Release 
Announced OnOct 22, 2021

Cadila Healthcare Limited has informed the Exchange regarding a press release dated October 22, 2021, titled " Zydus announces first patient randomised in EVIDENCES-XTM Phase II(b) clinical trial of Saroglitazar Mg in NASH ". | Download

Cadila Healthcare Limited has informed the Exchange regarding a press release dated October 22, 2021, titled " Zydus announces first patient randomised in EVIDENCES-XTM Phase II(b) clinical trial of Saroglitazar Mg in NASH ". | Download

Cash Dividend 
Ex. DateJul 28, 2021

Final • Div/Share: ₹ 3.5

See all events